Changes to the website

Sponsored by

xCures

Please click on the above banner for more details

WEBSITECHANGES

You can Subscribe to our RSS FEED: which delivers brain tumor news and additions to the website via RSS.

Click HERE for details on RSS.

Displaying items 1326 to 1350 of about 5877

Previous 25

Website Changes

12/29/2017

Musella Foundation awards brain tumor research grant!

12/29/2017

Charitable giving to take a hit from the tax law

12/28/2017

Foundation Aims For Virtual Trial Registry To Help Patients With Brain Cancer Get Drugs Sooner

12/27/2017

Cancer Drug Price Rises 1,400% With No Generic to Challenge It

12/27/2017

Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial with TSC in Glioblastoma Multiforme

12/26/2017

DelMar Pharmaceuticals announces Fast Track designation for VAL-083 in recurrent Glioblastoma

12/23/2017

Musella Foundation awards brain tumor research grant!

12/23/2017

Musella Foundation Co-pay Assistance Program Status

12/23/2017

Highlights from the Society for Neuro Oncology annual meeting, San Francisco California, November 16-19 2017

12/19/2017

JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma

12/07/2017

Recurrent glioma clinical trial, CheckMate-143: the game is not over yet

12/06/2017

FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer

12/04/2017

A novel immuno-oncology approach to treating a rare childhood brain cancer

12/03/2017

Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma.

12/03/2017

Correction regarding dose of Avastin in an old article

12/02/2017

Promising target for treating brain tumors in children

12/02/2017

Novocure (NVCR) Announces Reimbursement Approval for Optune in Japan for Treatment of Newly Diagnosed GBM

12/02/2017

Novel Agents for GBM and Glioma From SNO 2017

12/02/2017

Key Trials on Gliomas at SNO 2017

12/02/2017

SNO 2017: No Unexpected Safety Issues Arise With Tumor Treating Fields in Glioblastoma Patients With Shunts, Pacemakers, or Defibrillators

12/02/2017

SNO 2017: Toca 511/FC Lead to Durable Responses in IDH1 Wildtype and Mutant Recurrent High-Grade Glioma

12/02/2017

Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma

12/02/2017

Researchers identify vulnerability for glioblastoma subtypes

12/02/2017

Novel Agents for GBM: A Review of Trials at SNO 2017

12/01/2017

FDA Aims to Expand Early-Approval Program for Promising Drugs

Our privacy / cookie policy has changed.
Click HERE to read it!